Deep Remission Tied to RA Control
At 5 years, 63% of patients in the CliDR group maintained sustained remission compared with 38% in the non-CliDR group.
-
By
-
Andrea Surnit
-
May 6, 2026
-
Clinical Scorecard: Deep Remission Tied to RA Control
At a Glance
| Category | Detail |
|---|
| Condition | Rheumatoid Arthritis |
| Key Mechanisms | Clinical deep remission (CliDR) reflects complete absence of clinically detectable joint inflammation. |
| Target Population | Patients with rheumatoid arthritis achieving remission based on DAS28-CRP. |
| Care Setting | Single-center observational cohort study. |
Key Highlights
- 63% of patients in the CliDR group maintained sustained remission at 5 years.
- Relapse occurred in 12 of 32 patients in the CliDR group versus 70 of 113 in the non-CliDR group.
- Tapering was associated with an 8.5-fold higher relapse hazard in non-CliDR patients.
Guideline-Based Recommendations
Diagnosis
- Use DAS28-CRP for assessing remission in rheumatoid arthritis.
Management
- Consider achieving clinical deep remission (CliDR) for better long-term outcomes.
Monitoring & Follow-up
- Regular DAS28-CRP assessments to evaluate remission status.
Risks
- Increased relapse risk associated with treatment tapering in non-CliDR patients.
Patient & Prescribing Data
Patients with rheumatoid arthritis, predominantly anti-CCP positive.
CliDR may provide additional prognostic information for medication tapering decisions.
Clinical Best Practices
- Aim for clinical deep remission to improve sustained remission rates.
- Evaluate tapering strategies carefully in patients who have achieved CliDR.
Related Resources & Content
